Key facts
- It has raised $99.0M; the latest was Later Stage VC ($40.0M) in Jun 2025.
- Notable investors include Perceptive Advisors, CinRx Pharma.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for CinDome Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for CinDome Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CinDome Pharma
Provider of drugs for treating gastrointestinal diseases based in Cincinnati, Ohio. The company provides drugs for treating diseases and developing a novel chemical entity, CIN-102, through the process of deuteration, enabling customers to have safe, effective, and tolerable treatment for chronic gastroparesis.
- Sector
- Healthcare
- HQ
- Cincinnati, OH, United States
- Founded
- 2019
- Website
- cindome.com/
- Ownership
- Privately Held (backing)
CinDome Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CinDome Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CinDome Pharma in its N-PORT filings yet. We sweep new filings monthly.